Jazz Pharmaceuticals plc JAZZ Income Statement

Jazz pharmaceuticals plc (JAZZ)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
Royalties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	630	674
Contract revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	285	284
Total revenues
534,726	581,740	537,702	534,133	508,186	476,457	469,373	500,479	444,613	436,399	411,855	394,386	376,053	396,621	374,181	381,161	336,010	340,881	340,872	333,747	309,303	328,142	306,584	291,230	246,919	235,774	232,160	208,252	196,237	183,703	175,515	124,231	102,530	83,536	73,293	64,567	50,881	44,753	40,486
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)
28,657	35,348	31,400	27,676	33,506	26,337	26,574	34,714	33,919	25,248	31,203	28,672	25,065	33,656	24,311	23,980	23,439	24,030	28,385	21,813	28,298	28,808	26,994	30,692	30,924	25,643	24,252	25,031	27,220	25,763	32,629	12,289	7,744	3,862	3,901	3,370	2,809	3,091	2,802
Selling, general and administrative
208,400	214,275	178,706	176,014	167,947	161,865	155,873	158,579	207,213	143,050	124,523	132,328	144,255	127,141	124,368	122,618	128,765	125,555	104,044	107,132	112,388	105,694	93,501	100,556	106,363	81,299	74,970	77,506	70,528	61,378	60,924	57,224	44,356	36,384	30,547	22,094	19,911	18,040	17,096
Research and development
86,107	97,382	79,855	62,384	60,105	56,657	51,160	56,132	62,667	65,995	47,362	40,157	44,928	44,158	47,796	39,091	31,252	29,455	50,784	27,833	27,181	24,559	22,423	20,090	18,109	13,809	11,826	9,250	6,747	7,277	6,920	2,321	3,959	3,764	3,279	3,382	3,695	7,317	7,962
Intangible asset amortization
62,847	173,490	62,863	61,576	56,885	46,543	46,989	54,959	53,007	52,901	47,313	26,186	25,665	26,162	26,453	26,737	22,642	23,690	26,127	23,668	24,677	31,977	30,630	32,795	31,182	20,524	19,564	19,399	19,555	21,907	19,742	12,970	10,732	1,862	1,862	1,862	1,862	1,862	2,044
Acquired in-process research and development
202,250	0	51,775	2,200	56,000	0	0	0	0	-	75,000	2,000	-	0	15,000	0	8,750	0	0	0	0	626	75,000	0	127,000	0	988	0	4,000	-	-	-	-	-	-	-	-	-	-
Impairment charge
136,139	0	0	0	0	-	0	42,896	-	-	0	0	-	-	-	-	-	-	-	-	-	-	0	32,806	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
724,400	520,495	404,599	329,850	374,443	291,402	280,596	347,280	356,806	295,194	325,401	229,343	239,913	231,117	237,928	212,426	214,848	234,253	209,340	180,446	192,544	198,223	248,548	216,939	313,578	141,275	131,600	131,186	128,050	116,325	120,215	84,804	66,791	45,872	39,589	30,708	28,277	30,310	29,904
Income (loss) from operations
-189,674	61,245	133,103	204,283	133,743	185,055	188,777	153,199	87,807	141,205	86,454	165,043	136,140	165,504	136,253	168,735	121,162	106,628	131,532	153,301	116,759	129,919	58,036	74,291	-66,659	94,499	100,560	77,066	68,187	67,378	55,300	39,427	35,739	37,664	33,704	33,859	22,604	14,443	10,582
Interest expense, net
-18,496	-18,244	-17,861	-18,234	-17,922	-17,904	-18,920	-19,646	-20,605	-21,426	-19,192	-18,294	-18,844	-19,131	-18,498	-12,121	-12,192	-12,210	-12,650	-15,812	-16,245	-16,678	-14,530	-11,429	-10,076	-6,173	-6,202	-7,142	-7,399	-7,651	-7,750	-1,481	13	-1,595	-125	-657	777	1,197	4,687
Foreign exchange loss
-1,132	-2,234	-1,033	-1,933	-611	-1,694	-756	-2,697	-1,728	-854	-2,224	-5,427	-1,464	4,940	-749	0	-819	2,091	-977	-1,914	2,245	2,003	6,483	74	123	-969	-614	-385	271	-4,959	1,099	240	0	-	0	-	-	-	-
Gain (Loss) on Extinguishment and Modification of Debt
-	-	0	0	-	-	0	-1,425	-	-	0	0	-	-	-638	-	-	-	0	-16,815	-	-	0	0	-	-	0	-3,749	-	-	0	0	-	-	-1,097	-	-	-	-12,287
Income (loss) before income tax provision (benefit) and equity in loss (gain) of investees
-209,302	40,767	114,209	184,116	115,210	165,457	169,101	129,431	65,474	118,925	65,038	141,322	115,832	151,313	116,368	156,614	108,151	96,509	117,905	118,760	102,759	115,244	49,989	62,936	-76,612	87,357	93,744	65,790	61,059	57,446	46,451	37,706	35,752	37,473	32,482	33,202	21,827	-	-
Interest income and other, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	4
Income tax provision (benefit)
-51,300	-34,500	10,900	-78,700	29,100	5,254	19,300	36,500	19,146	-113,614	1,239	35,515	29,160	34,348	26,437	42,112	32,339	13,748	29,945	30,647	32,059	33,633	24,221	19,350	17,027	32,064	18,335	23,605	17,634	-108,760	12,856	6,593	5,517	-	0	0	-	-	-
Equity in loss (gain) of investees
182	-1,298	-1,030	-868	-893	-843	-437	-586	-337	-372	-273	-203	-161	-276	-103	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166,206	33,595	31,113	30,235	-	32,482	-	-	-	-
Income from discontinued operations, net of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,345	-386	-3,968	-2,554	-	0	-	-	-	-
Net income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	82,761	87,960	88,113	70,700	81,611	25,768	43,586	-93,639	55,293	75,409	42,185	43,425	-	-	-	-	-	-	-	-	-	-
Net loss attributable to noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1	-	-1	2	-73	-989	0	0	0	0	-	-	-	-	-	-	-	-	-	-
Net Income (Loss) Attributable to Parent
-157,833	73,992	102,276	261,898	85,201	159,470	149,316	92,321	45,991	232,207	63,526	105,604	86,511	116,689	89,828	114,502	75,812	-	87,960	88,114	-	81,612	25,766	43,659	-92,650	55,293	75,409	42,185	43,425	200,551	33,209	27,145	27,681	37,473	32,482	33,202	21,827	13,243	-6,388
Net income (loss) per ordinary share:
Basic:
Income from continuing operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.91	0.59	0.55	0.56	-	0.77	-	-	-	-
Income from discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.61	-0.01	-0.07	-0.05	-	0.00	-	-	-	-
Basic (in dollars per share)
-2.82	1.31	1.80	4.62	1.49	2.68	2.47	1.53	0.77	3.87	1.06	1.76	1.44	1.94	1.49	1.89	1.24	1.35	1.43	1.44	1.16	1.40	0.43	0.73	-1.58	0.95	1.30	0.72	0.74	3.52	0.58	0.48	0.51	0.89	0.77	0.81	0.54	0.34	-0.18
Diluted:
Income from continuing operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.75	0.56	0.51	0.52	-	0.69	-	-	-	-
Income from discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.56	-0.01	-0.06	-0.04	-	0.00	-	-	-	-
Diluted (in dollars per share)
-2.82	1.28	1.78	4.56	1.47	2.64	2.41	1.50	0.75	3.80	1.03	1.72	1.41	1.90	1.45	1.85	1.21	1.32	1.39	1.40	1.12	1.40	0.41	0.70	-1.58	0.88	1.23	0.69	0.71	3.31	0.55	0.45	0.48	0.79	0.69	0.71	0.48	0.32	-0.18
Weighted-average ordinary shares used in per share calculations - basic (in shares)
55,956	56,409	56,674	56,707	57,206	59,323	60,476	60,177	59,928	59,984	60,108	60,100	59,880	59,922	60,437	60,499	61,142	61,500	61,435	61,190	60,803	60,634	60,305	59,519	58,526	57,880	58,217	58,737	58,358	57,994	57,703	56,952	53,923	42,397	42,028	41,209	40,362	38,965	35,423
Weighted-average ordinary shares used in per share calculations - diluted (in shares)
55,956	57,254	57,438	57,427	58,081	60,411	61,857	61,438	61,178	61,191	61,436	61,463	61,178	61,026	61,795	62,043	62,616	62,936	63,154	63,090	62,964	66,872	62,680	62,378	58,526	61,678	61,519	61,568	61,511	61,259	60,883	60,554	58,084	47,653	47,241	46,601	45,697	41,737	35,423
Product sales, net
Total revenues
530,205	576,526	532,321	523,423	503,331	467,334	465,197	496,095	440,847	430,095	407,971	389,655	373,678	392,614	371,621	379,110	333,916	338,924	338,754	332,106	307,035	324,223	304,407	289,100	244,986	233,796	230,386	206,564	194,652	181,943	174,130	123,002	101,452	80,935	72,216	63,464	49,903	43,838	39,528
Royalties and contract revenues
Total revenues
4,521	5,214	5,381	10,710	4,855	9,123	4,176	4,384	3,766	6,304	3,884	4,731	2,375	4,007	2,560	2,051	2,094	1,957	2,118	1,641	2,268	3,919	2,177	2,130	1,933	1,978	1,774	1,688	1,585	1,760	1,385	1,229	1,078	2,601	1,077	1,103	978	-	-